Bariatric surgery in patients with first-degree obesity: is the surgical approach reasonable?

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The widespread progression of obesity, the insufficient effectiveness and stability of conservative approaches in its treatment and the corresponding development of bariatric surgery drive the need to study the potential and safety of performing surgery in patients with first-degree obesity. The article analyzes the literature data of research results presenting the experience of bariatric surgery application in patients with a body mass index (BMI) equal to 30-34 kg/m2, comparing the outcomes of surgery and the use of conservative treatment options for obesity and evaluating the effectiveness and safety of various types of bariatric surgery in this group of patients.

Due to controversy of the issue currently being discussed, the aim of the study was to assess the safety, effectiveness, and reasonability of bariatric interventions in patients with a relatively small excess weight based on available literature data.

Full Text

Restricted Access

About the authors

Aleksandra Igorevna Mitsinskaya

«Neuro-clinicа»

Author for correspondence.
Email: sashaart2012@yandex.ru

Ph.D., surgeon

Russian Federation, Moscow

Mikhail Mitsinskiy

«Neuro-clinicа»

Email: mic-mikhail@yandex.ru

surgeon

Russian Federation, Moscow

Azat Danisovich Akhmetov

«Neuro-clinicа»

Email: manysha7@yandex.ru

surgeon

Russian Federation, Moscow

References

  1. Alferova VI, Mustafina SV. The prevalence of obesity in the adult population of the Russian Federation (literature review). Obesity and metabolism. 2022; 19:1: 96-105.(in Russ.)
  2. Dedov II, Shestakova MV, Mel'nichenko GA, Mazurina NV, Andreeva EN, Bondarenko IZ, Gusova ZR, Dzgoeva FKh, Eliseev MS, Ershova EV, Zhuravleva MV, Zakharchuk TA, Isakov VA, Klepikova MV, Komshilova KA, Krysanova VS, Nedogoda SV, Novikova AM, Ostroumova OD, Pereverzev AP, Livzan MA, Lyalyukova EA, Druk IV, Safronova SS, Khalashte AA, Martirosyan KA, Petrosyan VYu, Galakhov YaS. Ozhirenie: sovremennoe sostoyanie problemy, mezhdistsiplinarnyi podkhod (po materialam konsensusa vsemirnoi gastroenterologicheskoi organizatsii «Ozhirenie 2023» i Evropeiskogo Rukovodstva po lecheniyu ozhireniya u patsientov s zabolevaniyami zheludochno-kishechnogo trakta i pecheni). Eksperimental'naya i klinicheskaya gastroenterologiya. 2023;10:5-47. (in Russ.)
  3. Pleshchev IE, Nikolenko VN, Achkasov EE, Preobrazhensky YaI, Gridin LA, Shkrebko AN, Zoller MV. The effect of physical exercise and nutritional support on elderly and senile patients with sarcopenic obesity. Acta Biomedica Scientifica. 2024; 9(3): 14-25. (in Russ.)
  4. Fursov RA, Ospanov OB. The obesity paradox: new facts as an example of reverse epidemiology. breast cancer. Medical review. 2019; 3(1): 16-20. (in Russ.)
  5. Starodubova AV, Starodubov VI. Trends, age and regional features of obesity incidence in the Russian Federation in 1992-2012. Preventive medicine. 2017; 20(6): 32-40. (in Russ.)
  6. Pavlovskaya EV, Strokova TV, Surkov AG, Bagaeva ME, Kaganov BS. The relationship between obesity and micronutrient status in children and adults. Nutrition issues. 2014; 4(2): 14-23. (in Russ.)
  7. Drapkina OM, Eliashevich SO, Shepel RN. Obesity as a risk factor for chronic infectious diseases. Russian Journal of Cardiology. 2016; 21(6): 73-79. (in Russ.)
  8. Nurieva AR, Sineglazova AV. Obesity. Phenotypes and comorbidity in the early stages of the cardiometabolic continuum. Vestnik sovremennoi klinicheskoi meditsiny. 2024; 17(4): 7-17. (in Russ.)
  9. Trushkina IV. Age-related aspects of cardiometabolic disorders in overweight patients. International Endocrinological Journal. 2011; 1(33): 79-91. (in Russ.)
  10. Mechanick JI, Kushner RF, Sugerman HJ, Gonzalez-Campoy JM, Collazo-Clavell ML, Spitz AF, Apovian CM, Livingston EH, Brolin R, Sarwer DB, Anderson WA, Dixon J, Guven S. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery Medical Guidelines for Clinical Practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Obesity (Silver Spring). 2009; 1: 1-70.
  11. Chumakova GA, Kuznetsova TYu, Druzhilov MA, Veselovskaya NG. Visceral obesity as a global cardiovascular risk factor. Russian Journal of Cardiology. 2018; 23(5): 7-14. (in Russ.)
  12. Dreval AV. A systematic approach to the prevention and treatment of obesity. Al'manakh klinicheskoi meditsiny. 2015; 1: 6-7. (in Russ.)
  13. Krysanova VS, Kelekhsaev PA. Socio-economic aspects of the problem of overweight and obesity. Medical business. 2020; 3: 100-107. (in Russ.)
  14. Biryukova EV. Obesity is a significant medical and social problem of our time: risk factors, pathophysiological determinants, therapy strategies. Consilium Medicum. 2024; 26(7): 461-469. (in Russ.)
  15. Samorodskaya IV. A new paradigm of obesity. Problems of endocrinology. 2014; 60(5): 43-48. (in Russ.)
  16. Molchanova OV, Bochkareva EV, Butina EK, Kim IV. The main causes of premature mortality in obesity. Preventive medicine. 2023; 26(12): 52-57. (in Russ.)
  17. Mustafina SV, Winter DA, Alferova VI. The influence of obesity on the formation and development of cancer. Obesity and metabolism. 2024; 21(2): 205-214. (in Russ.)
  18. Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006; 15: 872–8.
  19. Samorodskaya IV. Do we need new approaches to the assessment of obesity? Clinical medicine. 2015; 93(1): 29-34. (in Russ.)
  20. Chumakova GA, Veselovskaya NG, Gritsenko OV, Ott AV. Metabolic syndrome: complex and unresolved problems. Russian Journal of Cardiology. 2014; 19(3): 63-71. (in Russ.)
  21. Romantsova TI. The epidemic of obesity: obvious and probable causes. Obesity and metabolism. 2011; 8(1): 5-19. (in Russ.)
  22. Nguyen NT. Open vs. laparoscopic procedures in bariatric surgery. J Gastrointest Surg. 2004; 8(4): 393-395.
  23. Bobkova IN, Gussaova SS, Stavrovskaya EV, Struve AV. Nephrological aspects of body weight correction in morbid obesity. Terapevticheskii arkhiv. 2018 90(6): 98-104. (in Russ.)
  24. Salminen P, Nuutila P. Gastric Bypass vs Medical Treatment in Renoprotection for Patients with Class 1 Obesity, Type 2 Diabetes, and Albuminuria. JAMA Surg. 2020;155(12):e200420.
  25. Aminian A, Brethauer SA, Kirwan JP, Kashyap SR, Burguera B, Schauer PR. How safe is metabolic/diabetes surgery? Diabetes Obes Metab. 2015;17(2):198-201.
  26. Aminian A, Jamal MH, Andalib A. Is Laparoscopic Bariatric Surgery a Safe Option in Extremely High-Risk Morbidly Obese Patients? J Laparoendosc Adv Surg Tech A. 2015;25(9):707-711.
  27. Kermansaravi M. Current recommendations for procedure selection in class I and II obesity developed by an expert modified Delphi consensus. Sci Rep. 2024;14(1):3445.
  28. Li Q, Chen L, Yang Z. Metabolic effects of bariatric surgery in type 2 diabetic patients with body mass index < 35 kg/m2. Diabetes Obes Metab. 2012;14(3):262-270.
  29. Cohen RV, Pereira TV, Aboud CM. Effect of gastric bypass vs best medical treatment on early-stage chronic kidney disease in patients with type 2 diabetes and obesity: a randomized clinical trial. JAMA Surg. 2020;155(12):e200420.
  30. Ikramuddin S, Korner J, Lee WJ. Lifestyle intervention and medical management with vs without roux-en-y gastric bypass and control of hemoglobin a1c, LDL cholesterol, and systolic blood pressure at 5 years in the diabetes surgery study. JAMA. 2018;319(3):266-278.
  31. O'Brien PE. Bariatric surgery: mechanisms, indications and outcomes. J Gastroenterol Hepatol. 2010;25(8):1358-1365.
  32. Kermansaravi M. Current recommendations for procedure selection in class I and II obesity developed by an expert modified Delphi consensus. Sci Rep. 2024;14(1):3445.
  33. Ramírez EM, Espinosa O, Berrones R, Sepúlveda EM, Guilbert L, Solís M, Zerrweck C. The Impact of Preoperative BMI (Obesity Class I, II, and III) on the 12-Month Evolution of Patients Undergoing Laparoscopic Gastric Bypass. Obes Surg. 2018;28(10):3095-3101.
  34. Gero D, Raptis DA, Vleeschouwers W. Defining global benchmarks in bariatric surgery: a retrospective multicenter analysis of minimally invasive roux-en-y gastric bypass and sleeve gastrectomy. Ann Surg. 2019;270(5):859-867.
  35. Gamme G, Dang JT, Switzer N, Gill R, Birch DW, Karmali S. Evaluating the safety of bariatric surgery for weight loss in class I obesity: A propensity-matched analysis of North American data. Surg Obes Relat Dis. 2019;15(4):629-635.
  36. Bogdanov AR, Derbeneva SA, Pogozheva AV, Sentsova TB. Evaluation of the effectiveness of diet therapy in patients with varying degrees of obesity. Nutrition issues. 2014;83(6):32-40. (in Russ.)
  37. Sharafetdinov HH, Plotnikova OA. Obesity as a global challenge of the 21st century: therapeutic nutrition, prevention and therapy. Voprosy pitaniya. 2020;89(4):161-171. (in Russ.)
  38. Shestakova EA, Yashkov YuI, Rebrova OYu, Katz MV, Samsonova MD, Dedov II. Comparison of anamnestic characteristics, lifestyle features and concomitant diseases in obese patients with or without type 2 diabetes mellitus. Obesity and metabolism. 2020;17(4): 332-339. (in Russ.)
  39. Derbeneva SA, Bogdanov AR. The use of nutritional support to correct the metabolic status of obese patients. Voprosy pitaniya. 2015;84(5):34. (in Russ.)
  40. Avenell A, Brown TJ, McGee MA, Campbell MK, Grant AM, Broom J, Jung RT, Smith WCS. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet. 2004;17(4):293-316.
  41. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo controlled, phase 3 trial. Lancet. 2011;377(9774):1341-1352.
  42. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605.
  43. Amin A, Siddiq G, Haider MI, Choudry UK, Nazir I. Laparoscopic Sleeve Gastrectomy versus Lifestyle Modification in Class I Obesity in Pakistani Population: A Prospective Cohort Study. Cureus. 2019;11(6):e5031.
  44. Vitiello A, Angrisani L, Santonicola A, Iovino P, Pilone V, Forestieri P. Bariatric Surgery Versus Lifestyle Intervention in Class I Obesity: 7-10-Year Results of a Retrospective Study. World J Surg. 2019;43(3):758-762.
  45. Gudzune KA, Kushner RF. Medications for Obesity: A Review. JAMA. 2024;332(7):571-584.
  46. Singh D, Baksi A, Ramana P, Singla V, Aggarwal S. Five-Year Outcomes of Sleeve Gastrectomy in Patients with Class I Obesity and Type 2 Diabetes Mellitus. Obes Surg. 2022;32(1):96-102.
  47. Melekhina AS. Stigmatization of obesity. Voprosy pitaniya. 2018; 87: 5: 101-102. (in Russ.)
  48. Evdoshenko VV, Fedenko VV, Bordan NS, Matveev NL, Tsepkovsky AS. Gastric bypass surgery with one anastomosis on a short loop. Khirurgiya. Zhurnal imeni N.I. Pirogova. 2020; 11: 37-47.(in Russ.)

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Mitsinskaya A.I., Mitsinskiy M., Akhmetov A.D.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies